2017
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Seminars In Cancer Biology 2017, 52: 103-109. PMID: 29183778, PMCID: PMC5970946, DOI: 10.1016/j.semcancer.2017.11.019.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaCell lung carcinomaLung cancerWorld Health OrganizationLung carcinomaSignificant prognostic impactLung cancer patientsRecent large-scale genomic studiesSmall biopsy specimensDriver gene mutationsPrognostic impactCancer patientsBiopsy specimensTargeted therapyOncologic practiceAccurate subclassificationIHC biomarkersImmunohistochemical markersPatient careAccurate diagnosisImmunotherapyTherapyCancerSubclassificationCritical role
2000
Follow-up care for cancer: making the benefits equal the cost.
Schwartz D, Billingsley K, Wallner K. Follow-up care for cancer: making the benefits equal the cost. Oncology 2000, 14: 1493-8, 1501; discussion 1502-5. PMID: 11098513.Peer-Reviewed Original ResearchConceptsRecent consensus recommendationsSurvey of cliniciansInstitutional followUnproven regimensClinical outcomesClose surveillanceCommon cancerOncologic practiceConsensus recommendationsOncology organizationsFollowCancerCliniciansCareCurrent dataSignificant benefitsRegimensColorectalPatientsProstateBreastAcute need
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply